GAP43 and Alzheimer disease: The first study to validate AD-induced changes in synaptic protein biomarkers in plasma demonstrated that neuro-exosomal GAP-43 correlated with CSF GAP-43 and discriminated between controls, MCI, and AD patients (Jia et al., 2021), suggesting promising avenues for future research with blood-based biomarkers of synaptic dysfunction.